The
Complete Study is Immediately Accessible | Download the Sample Pages of this
Report@
The
drug discovery market is dominated by key industry leaders whose strong market
share and strategic initiatives shape the future direction of the industry.
- Pfizer Inc.
- GlaxoSmithKline PLC
- Merck
& Co. Inc. - Agilent
Technologies Inc. - Eli
Lilly and Company - F.
Hoffmann-La Roche Ltd - Bayer
AG - Abbott
Laboratories Inc. - AstraZeneca
PLC - Shimadzu
Corp
View
Detailed Insights of Drug Discovery Market 👉
Artificial
Intelligence (AI) In Drug Discovery Market Regional Outlook:
North America
dominated the artificial intelligence (AI) in drug discovery market in 2024.
The growth of the market is attributed to the early adoption of the
technologies by regional countries like the United States and Canada, which are
the major healthcare technology leaders, with the expanding investment in the
development of novel technologies in the pharmaceutical and biotechnology
industry driving the market growth. Additionally, the ongoing research on drug
discovery for different disease treatments boosts the growth of the market in the
region.
How Big is
the U.S. Artificial Intelligence (AI) In Drug Discovery Market Size?
According to
Precedence Research, The U.S. artificial intelligence (AI) in drug discovery
market size is expected to be worth approximately USD 6.93 billion by 2034, up
from USD 2.86 billion in 2025. In terms of CAGR, the market is projected to
grow at a double-digit CAGR of 10.26% from 2025 to 2034.
The United
States maintained its dominance in the artificial intelligence (AI) in
drug discovery market due to emerging and powerful AI startups and greater
government support for the implementation and innovation of the latest
technology. Moreover, the major pharmaceutical brands have invested heavily in
AI platforms to speed up drug production in the United States nowadays.
The Complete Study is Now Available
for Immediate Access | Download the Sample Pages of this Report@
Asia Pacific
is expected to have the fastest growth in the artificial intelligence (AI) in
drug discovery market during the forecast period. The increasing healthcare
infrastructural development in the economically developing countries in the
region, like China, India, Japan, South Korea, and others, is driving the
advancements in the drug discovery process. The inclination towards smart
technologies like AI and machine learning in biotechnology and pharmaceuticals
for drug development and novel treatment procedures contributed to the growth of
the market across the region.
China
China is
expected to emerge as a prominent country for artificial intelligence (AI) in
the drug discovery market in the coming years, owing to the rapid acceptance of
artificial intelligence and big data. Furthermore, the major companies in China
have seen under the development of heavy medical databases while using AI to
create personalized drugs and treatment in the country in recent years.
✚ Related Topics You May Find Useful:
➡️ Generative
AI in Drug Discovery Market: How algorithm-driven molecule generation is compressing
R&D timelines and transforming early-stage discovery pipelines
➡️ AI-Driven
Drug Discovery Platforms Market: Why computational platforms are
becoming the core infrastructure for target identification and lead
optimization
➡️ Artificial
Intelligence in Biopharmaceutical Market: How AI is accelerating biologics
development, manufacturing precision, and clinical decision support
➡️ AI
in Pharmaceutical Market: The shift toward automated clinical operations,
predictive analytics, and AI-enabled drug lifecycle management
➡️ Artificial
Intelligence in Precision Medicine Market: How AI models are unlocking deeply
personalized diagnostics, therapy selection, and treatment pathways
➡️ U.S.
Artificial Intelligence in Biotechnology Market: How U.S. biotech companies are
scaling AI to enhance gene editing, protein engineering, and cellular research
➡️ Artificial
Intelligence in Genomics Market: How machine learning is enabling
ultra-fast genome interpretation, variant detection, and disease prediction
➡️ Artificial
Intelligence in Bioinformatics Market: The role of AI in decoding complex
biological datasets and powering next-generation computational biology
➡️ Artificial
Intelligence in Biotechnology Market: Why AI-driven biological modelling
and automation are redefining lab workflows and bioprocess innovation
AI in Drug
Discovery Market Segmentation
Insights:
Type
Insights
The
preclinical and clinical trial portion segment dominated the
artificial intelligence (AI) in drug discovery market with the largest share in
2024. The rising advancements in healthcare, pharmaceuticals, and
biotechnology, with the association of AI, enhance the accuracy and efficiency
of drug development and clinical research functions. AI enhances speed and
accuracy in the clinical trial or testing portions. It provides accuracy in the
hypothesis generation and analysis for understanding the disease and enhanced
drug discovery process, adherence, monitoring, cohort composition, and endpoint
selection.
The drug
optimization segment is anticipated to grow rapidly over the forecast period.
Drug optimization is the process of evaluation and discovery of how
therapeutics or medications work on individual patients. The integration of AI
into the drug optimization method improves the efficiency of the process.
Drug Type
Insights
The small
molecule segment dominated the market with the largest share in 2024. Small
molecule drugs are the type of medicine that is designed to enhance and mimic
the natural substance behavior in the human body. AI can be applied to two
different types such as machines and deep learning, and generative AI. Machine
learning implements accelerated synthesis planning and predictive
retrosynthesis for novel molecular entities. Generative AI implemented for the
made for the libraries of new molecular entities depends on drug-like molecules
and synthetic accessibility scores accessibility.
The large
molecule segment is expected to show the fastest growth during the forecast
period. The large molecules are also known as the biologics obtained from
living organisms. The increasing demand for large molecule drugs for the
treatment of several chronic diseases. The implementation of AI into large
molecule development aims to improve the efficiency and productivity of large
molecule drug development.
Offering
Insights
The software segment dominated the market with the
largest share in 2024. The increasing adaptation of artificial intelligence
software in the pharmaceutical and biotechnology industry for drug development
and cost efficiency in the drug discovery process. Furthermore, the investment
by the major market players in the R&D activities on the novel launch of
software solutions drives the growth of the segment.
The service
segment is anticipated to grow rapidly over the forecast period. The increasing
demand for AI-based services by the leading pharmaceutical companies in the
drug discovery and development process is driving the growth of the
segment.
Technology
Insights
The machine
learning segment dominated the market with the largest share in 2024. Machine
learning technology is one of the major integral parts of artificial
intelligence. The integration of machine learning into drug discovery and
development helps in improving all aspects and applications of the process,
like target discovery, target validation, HIT discovery, HIT to lead, lead
optimization, pre-clinical studies, clinical trials, and post-development
monitoring and pharma vigilance. It improves the decision-making process in
pharmaceutical data.
Application
Insights
The oncology
segment accounted for the largest artificial intelligence (AI) in drug
discovery market share in 2024. The rising prevalence of cancer in the
worldwide population due to the changing environmental factors, genetics, and
lifestyle boosts the demand for effective treatment and medication processes.
The integration of artificial intelligence into cancer diagnostics aims to
improve the efficiency of the treatment and achieve better patient outcomes.
The AI predicts the chances of getting cancer in the future period with
predictive technology. It helps with cancer treatment, like chemotherapy and
surgeries.
The infection
segment is expected to show the fastest growth during the forecast period. The
integration of AI into infectious disease control transforms the diagnostic
process. It offers rapid diagnostics, antibiotic discovery, and addresses
several other challenges associated with infectious disease.
End User
Insights
The
pharmaceutical and biotechnology companies segment dominated the market with
the largest share in 2024. The rising economic conditions in developing
countries and the demand for efficient healthcare and pharmaceutical
infrastructure are driving the development of effective drug discovery and
treatment procedures. There are a number of leading pharmaceutical and
biotechnology companies adopting AI into their working operations to improve
productivity by reducing the cost of operations and manual errors.
The academics
and research segment is expected to show the fastest growth during the forecast
period. The increasing investment in the research and development program in
drug discovery studies in the research and academic institutions, and the
government support for the expansion of the healthcare research and academic
institutes, accelerate the growth of the segment.
You can
place an order or ask any questions, please feel free to contact at [email protected] | +1 804
441 9344
AI in Drug
Discovery Market Top Companies
➢ NVIDIA CORPORATION
➢ Microsoft Corporation
➢ INSILICO MEDICINE INC.
➢ Schrödinger
➢ EXSCIENTIA
➢ Cloud Pharmaceuticals
➢ CLOUD PHARMACEUTICAL
➢ TOMWISE, INC
What
is Going Around the Globe?
🔸In February 2025, Variational AI, an organization
behind Enki™, a leading firm in the advanced foundation model for small
molecule drug discovery, completed its oversubscribed USD 5.5 million Seed
extension round.
🔸In January 2025, Innophore and NVIDIA collaborated to
launch the AI-driven drug safety screening platform ‘CavitOmiX’ in January
2025. The platform uses NVIDIA’s computing power and specialties to increase
the silico drug design by protein binding site analysis.
🔸In February 2025, Venture capitalist and LinkedIn
co-founder Reid Hoffman entered healthcare with the launch of their startup
Manas AI. The new startup will work on drug development with the integration of
AI to enhance the drug discovery process. The development is initiated by
aggressive cancer treatment.
🔸In July 2024, Exscientia plc expanded its business
with Amazon Web Services (AWS) to implement the cloud provider’s artificial
intelligence (AI) and machine learning (ML) services in its platform for
end-to-end automation and drug discovery.
Segments
Covered in the Report
By Type
🔹Preclinical and Clinical Testing
🔹Molecule Screening
🔹Target Identification
🔹De Novo Drug Design and Drug
Optimization
By Drug
Type
🔹Small Molecules
🔹Large Molecules
By Offering
🔹Software
🔹Services
By
Technology
🔹Machine Learning
→
Supervised Learning
→
Reinforcement Learning
→
Unsupervised Learning
→
Other Machine Learning Technologies
🔹Other Technologies
By
Application
🔹Neurology
🔹Infectious Disease
🔹Oncology
🔹Others
By End
User
🔹Pharmaceutical and Biotechnology
Companies
🔹Contract Research Organizations
🔹Academics and Research
🔹Others
By
Geography
🔹North America
→
U.S.
→
Canada
🔹Europe
→
U.K.
→
Germany
→
France
🔹Asia Pacific
→
China
→
India
→
Japan
→
South Korea
→
Rest of the World
🔹Latin America
→
Brazil
→
Rest of Latin America
🔹Middle East and Africa (MEA)
→
GCC
→
North Africa
→
South Africa
→
Rest of the Middle East and Africa
Thanks for reading you can also get individual
chapter-wise sections or region-wise report versions such as North America,
Europe, or Asia Pacific.
Don’t Miss Out! | Instant Access to This Exclusive
Report 👉
Stay
Ahead with Precedence Research Subscriptions
Unlock
exclusive access to powerful market intelligence, real-time data, and
forward-looking insights, tailored to your business. From trend tracking to
competitive analysis, our subscription plans keep you informed, agile, and
ahead of the curve.
Browse Our
Subscription Plans@
About Us
Precedence
Research is a global market intelligence and consulting powerhouse, dedicated
to unlocking deep strategic insights that drive innovation and transformation.
With a laser focus on the dynamic world of
life sciences, we
specialize in decoding the complexities of cell and
gene therapy,
drug development, and oncology markets, helping our clients stay ahead in
some of the most cutting-edge and high-stakes domains in healthcare. Our
expertise spans across the biotech and pharmaceutical ecosystem, serving
innovators, investors, and institutions that are redefining what’s possible in regenerative medicine, cancer care, precision therapeutics,
and beyond.
Web:
Our
Trusted Data Partners:
Towards Healthcare | Nova One Advisor | Onco
Quant | Statifacts
Get Recent
News 👉 /news
✚ Explore More Market
Intelligence from Precedence Research:
➡️ Digital
Therapeutics:
How software-based interventions are restructuring chronic-disease management
and clinical-grade behavioral therapy
➡️ Life
Sciences Growth:
Forces driving expansion across biotech, biopharma, and advanced therapeutic
platforms
➡️ Viral
Vector Gene Therapy Manufacturing: Manufacturing constraints,
scalability limits, and innovations shaping next-generation gene-delivery
systems
➡️ Wellness
Transformation:
How prevention-centric health models are shifting consumer behavior, product
pipelines, and care delivery
➡️ Generative
AI in Healthcare:
How generative models are unlocking new diagnostics, clinical automation, and
patient-care innovations
For Latest
Update Follow Us:
LinkedIn | Medium
| Facebook | Twitter
link